Video
Dr. Chae on Using Crizotinib to Treat MET+ NSCLC
Author(s):
Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.
Young Kwang Chae, MD, MPH, MBA, an associate professor of medicine at Northwestern Medicine Feinberg School of Medicine, discusses using crizotinib (Xalkori) to treat MET-positive patients with non—small cell lung cancer (NSCLC).
The current National Comprehensive Cancer Network guidelines mention MET amplification as well as MET exon 14 skipping mutation, explains Chae. Crizotinib, which was granted a breakthrough designation by the FDA in May 2018 for the treatment of patients with metastatic NSCLC with MET exon 14 alterations who progress after receiving platinum-based chemotherapy.
Early-phase data for crizotinib, according to Chae, shows a clean waterfall plot with tolerable toxicity and positive efficacy. The data appear promising and the drug will likely appear as a frontline treatment in the future for patients with MET-positive lung cancer, concludes Chae.
